Immune Design Appoints Stephen R. Brady Chief Business Officer

        Immune Design Appoints Stephen R. Brady Chief Business Officer

PR Newswire

SEATTLE and SAN FRANCISCO, Sept. 26, 2013

SEATTLE and SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ --Immune Design, a
biotechnology company focused on the development of novel immune-based
therapies for cancer and other chronic conditions, today announced the
appointment of Stephen R. Brady as its Chief Business Officer.


Mr. Brady brings extensive experience to lead Immune Design's business
functions, including strategic planning and corporate development activities.
His appointment in this new position is a reflection of the Company's maturing
immune-based therapeutic programs and productive platform technology.

"Steve is an experienced and accomplished executive with a successful track
record of executing successful business development and corporate strategies,"
said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune
Design. "He is a key addition to our expanded management team and will play an
important role in advancing and expanding our strategic activities."

"Immune Design's combination of both novel antigen-specific and innate
immunity approaches is an exciting potential advancement in the area of cancer
immunotherapy," said Mr. Brady. "I look forward to working with the team to
move existing programs forward and further expand the reach of the company's
platform technology in oncology, infectious disease and allergies."

Most recently, Mr. Brady served as Chief Business Officer for 3-V Biosciences,
Inc., where he led business and operations activities, including finance,
legal, corporate communications and strategic portfolio planning. Previously,
he served as Vice President of Corporate Development for Proteolix, Inc.,
where he was primarily responsible for corporate development and legal
affairs, including the sale of the Company to Onyx Pharmaceuticals for $851M
in 2009. Prior to his tenure with Proteolix, Mr. Brady served as Senior
Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served primarily
in business development and legal capacities. Mr. Brady was also a Vice
President with Lazard Venture Advisors, a division of Lazard Freres & Co,
LLC., and an associate in the New York and San Francisco offices of Morrison &
Foerster LLP. Mr. Brady received a B.A. in English from the University of
Oregon and a LL.M. from New York University School of Law.

The Immune Design Approach

Immune Design's immunotherapy approach is designed to both activate and
deliver tumor antigens to dendritic cells in vivo to trigger specific, broad,
and effective anti-tumor immune responses. The company's pipeline includes
LV305 and G305 product candidates generated from two distinct technologies.
Immune Design's proprietary lentiviral vector platform selectively targets
dermal DCs in vivo to induce a powerful and durable pool of tumor specific
cytotoxic T lymphocytes (CTLs). The company's synthetic TLR4 agonist, GLA, is
a powerful inducer of innate immunity on its own and also triggers a potent
and specific cellular and humoral anti-tumor immune response when it is
combined with a tumor antigen. The LV305 and G305 product candidates will be
individually tested in parallel in oncology indications and, upon
demonstration of safety and immunogenicity, will then be tested in
combination. These technologies may be applied in other allergy and infectious
disease settings as well.

About Immune Design
Immune Design is a privately held, clinical stage biotechnology company based
in Seattle, WA. Immune Design brings together some of the world's leaders in
the field of molecular immunology to develop a synergistic platform of
next-generation therapeutic vaccines designed to treat cancer, infectious
diseases, allergy, and autoimmune disorders. The company employs leading-edge
technologies that target dendritic cells for more precise activation of the
immune response. These include a novel lentiviral vector engineered to deliver
antigen-encoding nucleic acids directly to dendritic cells in vivo and a TLR4
agonist that activates dendritic cells by up-regulating key molecules for
efficient antigen presentation and produces Th1 cytokines to enhance the
immune response. For more information, visit

SOURCE Immune Design

Contact: Julie Rathbun, Rathbun Communications,,
Press spacebar to pause and continue. Press esc to stop.